DILIN - Prospective Study
NCT00345930
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to identify individuals who have suffered a liver injury arising as an idiosyncratic reaction to a prescription drug or a complementary and alternative medicine. Recently added acute cases enrollment that meets criteria to the protocol. Also added Fibroscans to the protocol that will be completed at baseline and follow-up on chronic subjects.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Liver Diseases
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 2 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Duke University
- Last updated on ClinicalTrials.gov
- April 8, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of Southern California · Los Angeles, CA
Indiana · 1
- Indiana University · Indianapolis, IN
Maryland · 1
- NIH Clinical Site · Bethesda, MD
Michigan · 1
- University of Michigan · Ann Arbor, MI
North Carolina · 1
- Univeristy of North Carolina at Chapel Hill · Chapel Hill, NC
Pennsylvania · 1
- Thomas Jefferson · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.